Table 2.
Comparison of three leading candidates for SARS-CoV-2 testing with laboratory manufactured DBS specimens.
| Binding Site | Euroimmun Spike | Euroimmun NCP | |
|---|---|---|---|
| Sample Size Tested | n = 165 | n = 161 | n = 144 |
| Dried Blood Spots Tested | Laboratory spotted from venepuncture collection – ADAPT study and biorepository | Laboratory spotted from venepuncture collection – ADAPT study and biorepository | Laboratory spotted from venepuncture collection – ADAPT study and biorepository |
|
Sensitivity (95% Confidence Interval) |
94.67% (86.9 – 98.53) |
100% (95.80 – 100) |
100% (95.14 – 100) |
|
Specificity (95% Confidence Interval) |
100% (95.1 – 100) |
96.0% (88.75 – 99.17) |
66.20% (53.99 – 77.00) |
|
Positive Predictive Value (95% Confidence Interval) |
100% | 95.74% (89.66-98.32) |
76.29% (69.71-81.81) |
|
Negative Predictive Value (95% Confidence Interval) |
95.74% (89.66-98.32) |
100% | 100% |
| Correlation (R2) | 0.96 | 0.96 | 0.96 |
|
Bias (95% Limits of Agreement) |
0.219 (-0.524 to 0.963) |
0.90 (-1.03 to 2.88) |
0.81 (-0.01 to 1.64) |
| DBS Approved Sample Type | Yes | Yes | Yes |
| DBS Elution Buffer Provided | No | Yes | Yes |
| DBS Elution Method Described | No | Yes | Yes |
| Incubation Temperature | Room temperature | 37°C | 37°C |